' New Standard of Care ' for HER2-Mutant NSCLC? ' New Standard of Care ' for HER2-Mutant NSCLC?
Patients with non –small cell lung cancer harboring HER2 mutations experienced durable activity and promising survival outcomes with trastuzumab deruxtecan, a new study shows.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | HER2 | Herceptin | Lung Cancer | Non-Small Cell Lung Cancer | Study